Detalhe da pesquisa
1.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol
; 202(5): 942-952, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246588
2.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407542
3.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826340
4.
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Haematologica
; 107(11): 2641-2649, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511672
5.
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
Eur J Haematol
; 106(6): 808-820, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33638218
6.
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care.
Arterioscler Thromb Vasc Biol
; 40(2): 301-308, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31875699
7.
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
J Allergy Clin Immunol
; 146(2): 356-366.e4, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32437738
8.
Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia.
Curr Opin Hematol
; 26(2): 119-123, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30608253
9.
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
N Engl J Med
; 374(26): 2530-41, 2016 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27355533
10.
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Am J Hematol
; 94(1): 46-54, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30290003
11.
Asciminib in Relapsed Chronic Myeloid Leukemia. Reply.
N Engl J Med
; 382(14): 1379, 2020 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242376
12.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
BMC Cancer
; 18(1): 359, 2018 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29609532
13.
Can any patients with chronic myeloid leukemia outside of a clinical trial have their tyrosine kinase inhibitor discontinued?
Curr Opin Hematol
; 24(2): 125-131, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28099274
14.
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Cancer
; 123(15): 2875-2880, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28387926
15.
Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms.
Am J Hematol
; 97(1): E7-E10, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34674293
16.
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Am J Hematol
; 92(11): 1214-1223, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28815757
17.
Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis.
Dermatol Online J
; 23(10)2017 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29469781
18.
Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.
Haematologica
; 106(2): 614-618, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299902
19.
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Am J Hematol
; 91(6): 606-16, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26971533
20.
Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Dermatology
; 232(1): 122-5, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352467